Nectar Lifesciences Reports Rs 67.92 Crore Loss in Q1 FY27

Nectar Lifesciences recorded a consolidated net loss of Rs 67.92 crore for the quarter ended June 30, 2026. The total income for the same period stood at Rs 3.36 crore, with Earnings Per Share (EPS) at a negative Rs 0.79.

Reader Takeaway: Loss widens post-divestment; new real estate venture eyed.

What just happened

Nectar Lifesciences announced its consolidated financial results for the first quarter of FY27, revealing a significant net loss of Rs 67.92 crore. This comes after the company sold a substantial portion of its business operations through a slump sale in the previous financial year. Despite the loss, the company reported total income of Rs 3.36 crore for the quarter.

Why this matters

The substantial loss underscores the impact of the recent business divestment on the company's short-term profitability. However, the company aims to pivot towards real estate projects, suggesting a strategic shift for future growth. Management assures that the company has sufficient liquidity and operates as a going concern.

The backstory

In the previous financial year, Nectar Lifesciences undertook a slump sale of a significant part of its business. This strategic move, while resulting in losses, aimed to improve the company's liquidity position. Following this, the company amended its object clause to explore real estate development opportunities.

What changes now

The company is actively evaluating opportunities in the real estate sector. It has also entered into a Business Transfer Agreement (BTA) with Capnest Health Care Private Limited to sell its Empty Hard Gelatin Capsule business for Rs 19.90 crore. Further, Nectar Lifesciences is assessing the monetization of non-core assets, including its Jammu unit and a parcel of land in Punjab.

Risks to watch

The company's future performance will depend on its ability to successfully execute its real estate ventures and monetize non-core assets. The transition from manufacturing to real estate development carries inherent risks, including market volatility and execution challenges.

Governance and Board Updates

Dr. Gunmala Suri was appointed as an Additional Director (Non-Executive Non-Independent) effective August 15, 2026, pending shareholder approval. The Audit Committee, SRC, and CSR Committee have been reconstituted. The 31st Annual General Meeting is scheduled for September 18, 2026.